Kinetics of sulbactam hydrolysis by β-lactamases, and kinetics of β-lactamase inhibition by sulbactam

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 12, 2017, Pages

  Shapiro, Adam B ^a  

^a Entasis Therapeutics   (United States)

Author keywords

lactamase; Kinetics; Sulbactam; Turnover number

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE ADC 7; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M 15; BETA LACTAMASE IMP 1; BETA LACTAMASE KPC 2; BETA LACTAMASE NDM 1; BETA LACTAMASE OXA 10; BETA LACTAMASE OXA 23; BETA LACTAMASE OXA 24; BETA LACTAMASE OXA 48; BETA LACTAMASE P99; BETA LACTAMASE SHV 5; BETA LACTAMASE TEM 1; BETA LACTAMASE VIM 1; SULBACTAM; UNCLASSIFIED DRUG; BETA LACTAMASE INHIBITOR;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG HYDROLYSIS; ENTEROBACTER CLOACAE; ENZYME INHIBITION; MICHAELIS MENTEN KINETICS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TURNOVER NUMBER; CHEMISTRY; CLASSIFICATION; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HYDROLYSIS; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; SPECIES DIFFERENCE;

ACINETOBACTER BAUMANNII; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; ENTEROBACTER CLOACAE; GENE EXPRESSION; HYDROLYSIS; KINETICS; PSEUDOMONAS AERUGINOSA; SPECIES SPECIFICITY; SULBACTAM;

EID: 85034969186     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01612-17     Document Type: Article

References (42)

1. Bush K, Bradford PA. 2016. -Lactams and -lactamase inhibitors: an overview. Cold Spring Harb Perspect Med 6:a025247. https://doi.org/10.1101/cshperspect.a025247.
2. Bush K. 2015. A resurgence of -lactamase inhibitor combinations effective against resistant Gram-negative pathogens. Int J Antimicrob Agents 46:483–493. https://doi.org/10.1016/j.ijantimicag.2015.08.011.
3. Drawz SM, Bonomo RA. 2010. Three decades of -lactamase inhibitors. Clin Microbiol Rev 23:160–201. https://doi.org/10.1128/CMR.00037-09.
4. Qin W, Panunzio M, Biondi S. 2014. -Lactam antibiotic renaissance. Antibiotics 3:193–215. https://doi.org/10.3390/antibiotics3020193.
5. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. 2013. Prevalence of -lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY antimicrobial surveillance program (2010). Antimicrob Agents Chemother 57:3012–3020. https://doi.org/10.1128/AAC.02252-12.
6. Betrosian AP, Douzinas EE. 2009. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol 5:1099–1112. https://doi.org/10.1517/17425250903145251.
7. Pfaller MA, Flamm RK, Duncan LR, Mendes RE, Jones RN, Sader HS. 2017. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013–2014). Diagn Microbiol Infect Dis 88:177–183. https://doi.org/10.1016/j.diagmicrobio.2017.02.020.
8. Xin X, Jian L, Xia X, Jia B, Huang W, Li C, Wang C, Zhou L, Sun X, Tang X, Huang Y, Zhu Y, Zhang W. 2013. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/ sulbactam in the treatment of respiratory and urinary tract infections. Ann Clin Microbiol Antimicrob 12:38. https://doi.org/10.1186/1476-0711-12-38.
9. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. 2004. In vitro activities of the -lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with -lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 48:1586 –1592. https://doi.org/10.1128/AAC.48.5.1586-1592.2004.
10. Chen H, Liu Q, Chen Z, Li C. 2017. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis. J Infect Chemother 23:278 –285. https://doi.org/10.1016/j.jiac.2017.01.005.
11. Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, deJonge B, O’Donnell J, Mueller JP, Tommasi RA, Miller AA. 2017. ETX2514 is a broad spectrum -lactamase inhibitor for the treatment of drug resistant Gram-negative infections, including those caused by Acinetobacter baumannii. Nat Microbiol 2:17104. https://doi.org/10.1038/nmicrobiol.2017.104.
12. Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M. 2014. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 78:429–436. https://doi.org/10.1016/j.diagmicrobio.2013.10.008.
13. Hall BG, Barlow M. 2005. Revised Ambler classification of -lactamases. J Antimicrob Chemother 55:1050–1051. https://doi.org/10.1093/jac/dki130.
14. Bush K, Jacoby GA. 2010. Updated functional classification of -lactamases. Antimicrob Agents Chemother 54:969–976. https://doi.org/10.1128/AAC.01009-09.
15. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA. 2010. Inhibitor resistance in the KPC-2 -lactamase, a preeminent property of this class A -lactamase. Antimicrob Agents Chemother 54:890–897. https://doi.org/10.1128/AAC.00693-09.
16. Alba J, Ishii Y, Thomson K, Moland ES, Yamaguchi K. 2005. Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing -lactamase. Antimicrob Agents Chemother 49:4760–4762. https://doi.org/10.1128/AAC.49.11.4760-4762.2005.
17. Brenner DG, Knowles JR. 1981. Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6- and 6-monodeuterio and of 6,6-dideuterio derivatives with RTEM -lactamase from Escherichia coli. Biochemistry 20:3680–3687. https://doi.org/10.1021/bi00516a003.
18. Imtiaz U, Billings EM, Knox JR, Mobashery S. 1994. A structure-based analysis of the inhibition of class A -lactamases by sulbactam. Biochemistry 33:5728 –5738. https://doi.org/10.1021/bi00185a009.
19. Meroueh SO, Roblin P, Golemi D, Maveyraud L, Vakulenko SB, Zhang Y, Samama J-P, Mobashery S. 2002. Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM -lactamase from Escherichia coli. J Am Chem Soc 124:9422–9430. https://doi.org/10.1021/ja026547q.
20. Delaire M, Labia R, Samama J-P, Masson J-M. 1992. Site-directed mu-tagenesis at the active site of Escherichia coli TEM-1 -lactamase. J Biol Chem 267:20600–20606.
21. Kalp M, Bethel CR, Bonomo RA, Carey PR. 2009. Why the extended-spectrum -lactamases SHV-2 and SHV-5 are “hypersusceptible” to mechanism-based inhibitors. Biochemistry 48:9912–9920. https://doi.org/10.1021/bi9012098.
22. Thomson JM, Distler AM, Bonomo RA. 2007. Overcoming resistance to -lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244. Biochemistry 46:11361–11368. https://doi.org/10.1021/bi700792a.
23. Marcoccia F, Bottoni C, Sabatini A, Colapietro M, Mercuri PS, Galleni M, Kerff F, Matagne A, Celenza G, Amicosante G, Perilli M. 2016. Kinetic study of laboratory mutants of NDM-1 metallo--lactamase and the importance of an isoleucine at position 35. Antimicrob Agents Chemother 60:2366–2372. https://doi.org/10.1128/AAC.00531-15.
24. Franceschini N, Caravelli B, Docquier J-D, Galleni M, Frère J-M, Amicosante G, Rossolini GM. 2000. Purification and biochemical characterization of the VIM-1 metallo--lactamase. Antimicrob Agents Chemother 44:3003–3007. https://doi.org/10.1128/AAC.44.11.3003-3007.2000.
25. Vessillier S, Docquier J-D, Rival S, Frere J-M, Galleni M, Amicosante G, Rossolini GM, Franceschini N. 2002. Overproduction and biochemical characterization of the Chryseobacterium meningosepticum BlaB metallo--lactamase. Antimicrob Agents Chemother 46:1921–1927. https://doi.org/10.1128/AAC.46.6.1921-1927.2002.
26. Perilli M, Caporale B, Celenza G, Pellegrini C, Docquier JD, Mezzatesta M, Rossolini GM, Stefani S, Amicosante G. 2007. Identification and characterization of a new metallo--lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. Antimicrob Agents Chemother 51: 2988–2990. https://doi.org/10.1128/AAC.00083-07.
27. Prosperi-Meys C, Llabres G, de Seny D, Soto RP, Valladares MH, Laraki N, Frere J-M, Galleni M. 1999. Interaction between class B -lactamases and suicide substrates of active-site serine -lactamases. FEBS Lett 443: 109–111. https://doi.org/10.1016/S0014-5793(98)01689-5.
28. Felici A, Amicosante G, Oratore A, Strom R, Ledent P, Joris B, Fanuel L, Frere JM. 1993. An overview of the kinetic parameters of class B -lactamases. Biochem J 291:151–155. https://doi.org/10.1042/bj2910151.
29. Faheem M, Rehman MT, Danishuddin M, Khan AU. 2013. Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor. PLoS One 8:e56926. https://doi.org/10.1371/journal.pone.0056926.
30. Labia R, Lelievre V, Peduzzi J. 1980. Inhibition kinetics of three R-factor-mediated -lactamases by a new -lactam sulfone (CP45899). Biochim Biophys Acta 611:351–357. https://doi.org/10.1016/0005-2744(80)90071-6.
31. Bret L, Chaibi EB, Chanal-Claris C, Sirot D, Labia R, Sirot J. 1997. Inhibitor-resistant TEM (IRT) -lactamases with different substitutions at position 244. Antimicrob Agents Chemother 41:2547–2549.
32. Mariotte-Boyer S, Nicolas-Chanoine MH, Labia R. 1996. A kinetic study of NMC-A -lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins. FEMS Microbiol Lett 143:29–33. https://doi.org/10.1111/j.1574-6968.1996.tb08457.x.
33. Yamaguchi A, Hirata T, Sawai T. 1983. Kinetic studies on inactivation of Citrobacter freundii cephalosporinase by sulbactam. Antimicrob Agents Chemother 24:23–30. https://doi.org/10.1128/AAC.24.1.23.
34. Sawai T, Tsukamoto K. 1982. Cefoxitin, N-formimidoyl thienamycin, clavulanic acid, and penicillanic acid sulfone as suicide inhibitors for different types of -lactamases produced by Gram-negative bacteria. J Antibiot (Tokyo) 35:1594–1602. https://doi.org/10.7164/antibiotics.35.1594.
35. Therrien C, Kotra LP, Sanschagrin F, Mobashery S, Levesque RC. 2000. Evaluation of inhibition of the carbenicillin-hydrolyzing -lactamase PSE-4 by the clinically used mechanism-based inhibitors. FEBS Lett 470:285–292. https://doi.org/10.1016/S0014-5793(00)01342-9.
36. Papp-Wallace KM, Taracila M, Wallace CJ, Hujer KM, Bethel CR, Hornick JM, Bonomo RA. 2010. Elucidating the role of Trp105 in the KPC-2 -lactamase. Protein Sci 19:1714–1727. https://doi.org/10.1002/pro.454.
37. Lamoureaux TL, Vakulenko V, Toth M, Frase H, Vakulenko SB. 2013. A novel extended-spectrum -lactamase, SGM-1, from an environmental isolate of Sphingobium sp. Antimicrob Agents Chemother 57:3783–3788. https://doi.org/10.1128/AAC.00808-13.
38. Lin S, Thomas M, Mark S, Anderson V, Bonomo RA. 1999. OHIO-1 -lactamase mutants: the Arg244Ser mutant and resistance to -lactams and -lactamase inhibitors. Biochim Biophys Acta 1432:125–136. https:// doi.org/10.1016/S0167-4838(99)00025-4.
39. Penwell WF, Shapiro AB, Giacobbe RA, Gu R-F, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BLM, Ehmann DE, Miller AA. 2015. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother 59:1680–1689. https://doi.org/10.1128/AAC.04808-14.
40. Evans BA, Amyes SGB. 2014. OXA-β-lactamases. Clin Microbiol Rev 27: 241–263. https://doi.org/10.1128/CMR.00117-13.
41. Miller A, Hackel M, Bouchillon S, DeJonge B, Tommasi R, Mueller J. 2016. Global surveillance of the activity of sulbactam combined with the novel -lactamase inhibitor ETX2514 against clinical isolates of Acinetobacter baumannii from 2014. Open Forum Infect Dis 3(Suppl 1):2243. https:// doi.org/10.1093/ofid/ofw172.1791.
42. Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Bethel CR, Thomson JM, Anderson VE, Barlow M, Rice LB, Tenover FC, Bonomo RA. 2005. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 -lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother 49:2941–2948. https://doi.org/10.1128/AAC.49.7.2941-2948.2005.